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ABSTRACT The bcr-abl chimeric oncoprotein exhibits
deregulated protein tyrosine kinase activity and is implicated
in the pathogenesis of Philadelphia chromosome (Ph)-positive
human leukemias, such as chronic myelogenous leukemia
(CML). Recently we have shown that the levels of the protein
tyrosine phosphatase PTP1B are enhanced in p210 bcr-abl-
expressing cell lines. Furthermore, PTP1B recognizes p210
bcr-abl as a substrate, disrupts the formation of a p210
bcr-ablyGrb2 complex, and inhibits signaling events initiated
by this oncoprotein PTK. In this report, we have examined
whether PTP1B effects transformation induced by p210 bcr-
abl. We demonstrate that expression of either wild-type
PTP1B or the substrate-trapping mutant form of the enzyme
(PTP1B-D181A) in p210 bcr-abl-transformed Rat-1 fibro-
blasts diminished the ability of these cells to form colonies in
soft agar, to grow in reduced serum, and to form tumors in
nude mice. In contrast, TCPTP, the closest relative of PTP1B,
did not effect p210 bcr-abl-induced transformation. Further-
more, neither PTP1B nor TCPTP inhibited transformation
induced by v-Abl. In addition, overexpression of PTP1B or
treatment with CGP57148, a small molecule inhibitor of p210
bcr-abl, induced erythroid differentiation of K562 cells, a
CML cell line derived from a patient in blast crisis. These data
suggest that PTP1B is a selective, endogenous inhibitor of
p210 bcr-abl and is likely to be important in the pathogenesis
of CML.
Chronic myelogenous leukemia (CML) is characterized by the
reciprocal chromosomal translocation 9:22, which generates
the Philadelphia chromosome (Ph) (1). This event occurs in
the pluripotent hematopoietic stem cell and transposes the
c-abl proto-oncogene on chromosome 9, encoding a protein
tyrosine kinase (PTK), to a new position downstream of the
second exon of the gene bcr on chromosome 22. This trans-
location generates a novel fusion gene, bcr-abl, that encodes a
chimeric protein, p210 bcr-abl, the PTK activity of which is
aberrantly regulated relative to c-Abl (2). Growth factor-
dependent lymphoid and myeloid cells are transformed in
culture into factor-independent and tumorigenic cells after
ectopic expression of p210 bcr-abl (3, 4). Furthermore, ex-
pression of p210 bcr-abl in transgenic mice has been shown to
cause a CML-like myeloproliferative disease (5–7). Therefore,
p210 bcr-abl appears to play a fundamental role as the primary
causative factor in CML (8).
The observation that production of p210 bcr-abl is the
initiating event in CML has focused attention on the tyrosine
phosphorylation-dependent signaling events triggered by this
oncoprotein. Progress has been made in defining critical
substrates for propagating such signals (9, 10). Nevertheless,
control over the state of tyrosine phosphorylation of proteins
in vivo is governed by the coordinated and competing actions
of both PTKs and protein tyrosine phosphatases (PTPs) (11).
PTPs have been identified in eukaryotes, prokaryotes, plants,
and viruses and comprise a large family of enzymes that will
rival the PTKs in structural diversity and complexity (12).
PTPs may either antagonize or potentiate PTK-induced sig-
naling in vivo and have been implicated in such fundamental
physiological processes as growth and proliferation, differen-
tiation, cytoskeletal function, as well as in the etiology and
pathogenesis of certain diseases (13). Therefore, characteriza-
tion of the PTPs that either potentiate or antagonize p210
bcr-abl-induced signaling and transformation would provide
critical insights into the genesis and development of CML.
Recently we have shown that PTP1B is up-regulated rapidly
and selectively after expression of p210 bcr-abl in a number of
CML model cell lines. A substrate-trapping mutant of PTP1B
(PTP1B-D181A), in which high affinity for substrate is main-
tained but catalytic function is impaired (14), forms a stable,
direct complex with p210 bcr-abl in vitro and upon expression
in COS cells. Furthermore, expression of either wild-type or
substrate-trapping mutant forms of PTP1B inhibited the bind-
ing of the adaptor protein, Grb2, to p210 bcr-abl and sup-
pressed p210 bcr-abl-induced, Ras-dependent transcriptional
activation in NIH 3T3 cells. In contrast, TCPTP, the closest
known relative of PTP1B, did not recognize p210 bcr-abl as a
substrate nor did it effect p210 bcr-abl-induced signaling.
Furthermore, neither PTP1B nor TCPTP recognized v-Abl,
which shares the same catalytic domain as p210 bcr-abl, as a
substrate or attenuated its signaling function. These data
suggest that PTP1B may function as a specific, negative
regulator of p210 bcr-abl signaling in vivo (15).
In this study, we have addressed the paramount question of
whether PTP1B can influence transformation induced by p210
bcr-abl. We show that ectopic expression of either wild-type or
substrate-trapping (D181A) mutant PTP1B in Rat-1 fibro-
blasts attenuated transformation by p210 bcr-abl, as illustrated
by reduced growth in soft agar, impaired proliferation under
reduced serum conditions, and decreased tumor formation in
nude mice. In contrast, TCPTP did not suppress transforma-
tion by p210 bcr-abl. In addition, neither PTP1B nor TCPTP
suppressed v-Abl-induced transformation. Furthermore ex-
pression of PTP1B, but not TCPTP, induced erythroid dif-
ferentiation of the CML cell line, K562, similar to the effect
observed after treatment of the cells with a chemical inhibitor
of p210 bcr-abl. These data stress the potential importance of
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PTP1B as a physiological negative regulator of the p210
bcr-abl oncoprotein PTK and thus as a controlling element in
the pathogenesis of CML.
MATERIALS AND METHODS
Cell Lines. Recombinant PTP1B-, PTP1B-D181A-, and
TCPTP-expressing retroviruses were constructed by inserting
full-length cDNAs into the pWZL-hygro vector. Helper-free
retroviral stocks were prepared by transient hyperexpression in
LinX, a retroviral packaging line derived from 293 cells (L.
Xie, D. Beach, and G.H., unpublished data). These retrovi-
ruses were used to infect Rat-1 fibroblasts expressing p210
bcr-abl or v-Abl. Drug-resistant populations were established
by culturing the infected cells for 14 days in 100 mgyml
hygromycin, refeeding every 3 days in the presence of the drug.
Cell Culture and Preparation of Lysates. Stable Rat-1
fibroblast lines expressing p210 bcr-abl and v-Abl were created
as described (16) and cultured in DMEM with 10% fetal
bovine serum (FBS). K562 cells were cultured in RPMI
medium 1640 with 10% FBS. Cells were lysed in 50 mM
TriszHCl (pH 7.5), 150 mM NaCl, 1% (volyvol) Triton X-100,
10% glycerol, 1 mM EDTA, 10 mgyml leupeptin, 10 mgyml
aprotinin, 1 mM benzamidine, and 1 mM phenylmethylsulfo-
nyl f luoride in the presence or absence of 1 mM Na3VO4.
Protein concentrations were determined by the Bradford
assay, using BSA as standard (17).
Antibodies, Immunoblotting, and Immunoprecipitation.
The following mAbs were used: anti-PTP1B, FG6, and anti-
TCPTP, CF4, were kindly provided by D. Hill (Calbiochem
Oncogene Research Products, MA); anti-Abl antibodies, 8E9
and K12, were from PharMingen and Santa Cruz, respectively;
anti-phosphotyrosine, 4G10 was from Upstate Biotechnology;
anti-Grb2 was from Transduction Laboratories (Lexington,
KY); and the mAb to a-globin was kindly provided by So-
matagen (Boulder, CO). For immunoprecipitation, lysates
were precleared with IgG Sorb (The Enzyme Center, Malden,
MA) reconstituted in lysis buffer, and then added to Protein
A Sepharose-coupled antibody. After rocking at 4°C for 90
min, immune complexes were collected by centrifugation for
10 s at 1,000 3 g, the supernatant was discarded, and the beads
were washed five times in 20 mM TriszHCl (pH 7.5), 150 mM
NaCl, 0.1% (volyvol) Triton X-100, 10% glycerol, 1 mM
EDTA, 10 mgyml leupeptin, 10 mgyml aprotinin, 1 mM
benzamidine, 1 mM phenylmethylsulfonyl f luoride, and 1 mM
Na3VO4. Samples were subjected to SDSyPAGE and trans-
ferred to nitrocellulose membranes. The membranes were
blocked with 5% nonfat dry milk in TBS-Tween, incubated
with the appropriate antibody for immunoblotting, and visu-
alized by ECL (Amersham).
Transformation Assays. (i) Anchorage-independent
growth: Equal numbers of viable cells were plated in 0.35%
noble agar in 10% FBS-containing medium at a density of 104
cells per 6 cm2 plate. The number of colonies formed in agar
was recorded 2 weeks after plating the cells (18). (ii) Growth
in reduced serum: At day 0, p210 bcr-abl-transformed Rat-1
fibroblasts, ectopically expressing the PTPs or control vector,
were seeded at a density of 104 cells per 10 cm2 plate in DMEM
supplemented with 1% FBS. Subsequently, every 2 days, the
culture medium was changed and cells were counted. (iii)
Tumor formation: Individual clones of p210 bcr-abl-
transformed Rat-1 fibroblasts expressing PTPs or control
vector (1 3 106 cells) were injected into each of the flanks of
BALByc nude mice (Taconic Farms). Two separate clones
were evaluated for each condition. Mice were monitored daily,
and 3 weeks after inoculation they were killed and the size of
the tumors recorded in grams wet weight. The data are
expressed as mean 6 SEM for each condition (four mice in
total, two mice per cell clone, inoculated at two sites each, i.e.,
eight tumor masses per condition).
Erythroid Differentiation Assay. K562 cells (2 3 106) were
washed, resuspended in 0.5 ml of RPMI medium 1640 sup-
plemented with 10% FBS, placed in a 0.4-cm gap electropo-
ration cuvette (GIBCOyBRL), and 25 mg of plasmid DNA
(pcDNA3, Invitrogen) expressing either PTP1B or TCPTP, or
control vector alone, was added. After a 10-min incubation at
room temperature, the cells were transiently transfected by
electroporation by using a single electric pulse (960 mF, 300V)
in a Bio-Rad Gene Pulser electroporator and then replated
into growth medium. At 24 h after transfection, cells were
resuspended in fresh media in the presence of 1 mgyml G418.
As a positive control, cells were transfected with control vector
and, 24 h after transfection, resuspended in fresh media and
treated with 10 mM CGP57418, a selective inhibitor of Abl
PTKs (19, 20). After 48 h, cells were harvested and lysates
analyzed for a-globin expression by immunoblotting.
RESULTS
As we reported previously, Rat-1 fibroblasts responded to
expression of p210 bcr-abl by increasing the levels of PTP1B
protein (Fig. 1, lanes 1 and 2), (15). Strikingly, we observed
that this increase was reversed in clonal, transformed lines
selected in soft agar from the mass (heterogeneous) popula-
tion of p210 bcr-abl-expressing Rat-1 fibroblasts (Fig. 1, com-
pare lanes 3 and 4 with lane 2). In contrast, the levels of
TCPTP and p210 bcr-abl remained unaltered after clonal
isolation of transformed cells. Immunoblotting of cell lysates
with antibodies to phosphotyrosine revealed that upon expres-
sion of p210 bcr-abl, the phosphorylation of tyrosyl residues in
proteins in the mass population of Rat-1 fibroblasts was
induced only marginally. A robust tyrosine phosphorylation
response was detected only after clonal selection of trans-
FIG. 1. Levels of PTP1B in p210 bcr-abl-expressing Rat-1 fibro-
blasts. Protein expression was determined by immunoblotting equal
quantities of lysate with the appropriate antibodies. Two gels were run,
one to determine the levels of PTP1B (Top panel) and p210 bcr-abl
(Third panel), the other to assess the state of tyrosine phosphorylation
of the various proteins in the lysate (Bottom panel) and the levels of
TCPTP (Second panel). Immunoblots were visualized by ECL. The
lanes represent: 1, parental Rat-1 fibroblasts; 2, heterogeneous (mass)
population of p210 bcr-abl-expressing Rat-1 fibroblasts; 3 and 4, soft
agar-derived clones of p210 bcr-abl-transformed Rat-1 fibroblasts,
lane 3 5 clone 5, lane 4 5 clone 10; 5, p210 bcr-abl-transformed clone
5 ectopically expressing PTP1B; 6–8, clones recovered in soft agar
from p210 bcr-abl-transformed clone 5 ectopically expressing PTP1B.
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formed lines and concomitant down-regulation of PTP1B.
These data are consistent with the possibility that PTP1B may
function to antagonize p210 bcr-abl-induced signaling and thus
transformation. To examine this issue further, we expressed
PTP1B ectopically in two, distinct p210 bcr-abl-transformed
Rat-1 fibroblast clones in which the level of the phosphatase
had been down-regulated as a result of clonal selection. After
infection of these cells with recombinant retroviruses, the
levels of PTP1B reached those observed after expression of
p210 bcr-abl in parental Rat-1 fibroblasts. As shown in Fig. 1
(lane 5), enforced expression of PTP1B in one of these lines
attenuated tyrosine phosphorylation. Similar results were ob-
tained in both lines. This observation prompted us to investi-
gate in detail the effects of PTP1B on p210 bcr-abl-induced
transformation.
Overexpression of PTP1B, but Not TCPTP, Suppressed
p210 bcr-abl-Induced Transformation of Rat-1 Fibroblasts.
Parental Rat-1 fibroblasts, Rat-1 fibroblasts expressing v-Abl,
and two independent soft agar-derived clones transformed by
p210 bcr-abl (clones 5 and 10) were infected with the PTP1B-
or TCPTP-expressing retroviruses. After selection of infected
cells, the levels of p210 bcr-abl, v-Abl, PTP1B, and TCPTP, as
well as the extent of tyrosine phosphorylation, were evaluated
by immunoblotting with appropriate antibodies (Fig. 2 A and
B). Expression of wild-type PTP1B in the p210 bcr-abl-
transformed Rat-1 fibroblast clones suppressed tyrosine phos-
phorylation without altering the levels of the PTK. In contrast,
no effect on tyrosine phosphorylation was evident after ex-
pression of TCPTP (Fig. 2A). Tyrosine phosphorylation was
enhanced in Rat-1 fibroblasts transformed by v-Abl, which
bears the same catalytic domain as p210 bcr-abl (21); however,
we did not detect an effect of expression of either PTP1B or
TCPTP on these phosphorylation events (Fig. 2B).
Rat-1 fibroblasts transformed by either v-Abl or p210 bcr-abl
display anchorage-independent growth, as measured by their
ability to form colonies in soft agar (18, 22). Ectopic expression
of wild-type or substrate-trapping mutant PTP1B in clonal,
p210 bcr-abl-transformed Rat-1 cell lines decreased by '60%
the number of colonies observed in soft agar, as compared with
p210 bcr-abl-transformed Rat-1 fibroblasts expressing either
TCPTP or a control vector (Table 1). Colonies derived from
Rat-1yp210 cells expressing either PTP1B or PTP1B-D181A
were small and acidification of the culture medium was not
detected. In contrast, we detected no attenuation of the ability
of v-Abl-transformed cells to form colonies in soft agar after
expression of either PTP1B or TCPTP (Table 1). Thus, the
effects of PTP1B appear to be selective for p210 bcr-abl.
Although expression of PTP1B markedly suppressed the
ability of p210 bcr-abl to induce anchorage-independent
growth of Rat-1 fibroblasts, the effect was not absolute.
Therefore, we tested the colonies that escaped this suppression
for expression of PTP1B. Interestingly, we noted that the level
of PTP1B in these colonies was similar to that observed in
parental Rat-1 fibroblasts (Fig. 1, lanes 6–8). The decline in
levels of PTP1B was accompanied by enhanced tyrosine
phosphorylation and occurred in the absence of an effect on
the level of expression of p210 bcr-abl or endogenous TCPTP.
These data suggest an inverse correlation between p210 bcr-
abl-induced transformation and the levels of PTP1B. Deple-
tion of PTP1B may be required for manifestation of the p210
bcr-abl-induced transformed phenotype.
Overexpression of PTP1B Inhibited the Growth of p210
bcr-abl Transformed Rat-1 Fibroblasts in Reduced Serum and
Tumor Formation in Nude Mice. Parental Rat-1 fibroblasts
typically require 10% FBS for proliferation in culture. How-
ever, transformation by p210 bcr-abl reduces this requirement,
allowing growth in medium containing 1% FBS (Fig. 3). Upon
transfer of either the control vector or the TCPTP expression
vector, p210 bcr-abl-transformed Rat-1 cells displayed sub-
stantial growth rates in 1% FBS. In contrast, overexpression of
either wild-type or substrate-trapping mutant PTP1B pro-
foundly inhibited proliferation in 1% FBS (Fig. 3).
Next, we evaluated the effect of ectopic expression of
PTP1B on p210 bcr-abl-induced tumorigenesis in vivo. Rat-1
fibroblasts transformed with p210 bcr-abl produced large
tumors after injection into nude mice (1.10 6 0.17 g wet tumor
weight). Overexpression of PTP1B in p210 bcr-abl-trans-
FIG. 2. Expression of PTP1B and TCPTP in p210 bcr-abl-
transformed (A) and parental and v-Abl-transformed Rat-1 fibroblasts
(B). (A) Equal quantities of lysate protein from Rat-1yp210 bcr-abl
(clone 5) cells were analyzed by immunoblotting with an anti-PTP1B
antibody (Top panel); the blot was stripped and reprobed with
anti-TCPTP antibody (Second panel). Expression and activation status
of p210 bcr-abl were analyzed on a second gel by immunoblotting with
an anti-pTyr antibody (Bottom panel), then stripping and reblotting
with anti-Abl antibody 8E9 (Third panel). (B) Equal quantities of
lysate protein from parental and v-Abl-transformed Rat-1 cells were
immunoblotted for expression of PTP1B (Top panel) and the blot was
stripped and reprobed with anti-TCPTP antibody (Second panel).
Tyrosine phosphorylation was determined on a second gel by immu-
noblotting with an anti-pTyr antibody (Bottom panel) and the blot was
stripped and reblotted with anti-Abl antibody 8E9 (Third panel).
Immunoblots were visualized by ECL.
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formed cells reduced, by 70–80%, the size of tumors formed
at 3 weeks after injection (PTP1B 0.26 6 0.08 g, PTP1B-
D181A 0.14 6 0.05). In contrast, the effect of expression of
TCPTP was much less pronounced (0.73 6 0.14 g). Thus, the
presence of PTP1B appears to interfere with the ability of
Rat-1 fibroblasts expressing p210 bcr-abl to form both colonies
in soft agar and tumors in nude mice.
Expression of PTP1B in p210 bcr-abl-Transformed Rat-1
Cells Disrupted the Association Between Grb2 and p210
bcr-abl. Our data illustrate that ectopic expression of PTP1B
suppresses the transformed phenotype of p210 bcr-abl-
expressing Rat-1 fibroblasts. Transformation of fibroblasts by
p210 bcr-abl is dependent upon the adaptor protein Grb2,
which links p210 bcr-abl to the Ras-signaling cascade (16, 23).
We recently reported that coexpression of p210 bcr-abl with
PTP1B in COS cells disrupted the association of the PTK with
endogenous Grb2 (15). To address the mechanism by which
PTP1B suppressed p210 bcr-abl-induced transformation, we
examined the effect of the PTP on association of Grb2 with
p210 bcr-abl in Rat-1 fibroblasts. Rat-1yp210 cells expressing
the various PTPs were lysed, p210 bcr-abl was immunopre-
cipitated, and the levels of associated Grb2 were determined
(Fig. 4). We observed that the association between p210
bcr-abl and Grb2 was disrupted in cells expressing either
wild-type or substrate-trapping mutant PTP1B, but not in cells
expressing TCPTP.
PTP1B-Induced Differentiation of the Human Ph-Positive
Leukemic Cell Line K562. The studies described above have
focused on an analysis of the effects of PTP1B on p210
bcr-abl-induced transformation of fibroblasts. However, it is
important also to examine this issue in hematopoietic cells,
wherein p210 bcr-abl is a causative agent in human disease.
K562 cells, a p210 bcr-abl-expressing cell line established from
a CML patient in blast crisis, retain their capacity to differ-
entiate along megakaryocytic, erythroid, or monocytic lin-
eages following appropriate stimuli (24). Previous studies have
demonstrated that inhibition of the kinase activity of p210
bcr-abl induces erythroid differentiation of K562 cells (25).
Recently, CGP57148, a 2-phenylaminopyrimidine derivative,
was reported to inhibit the kinase activity of p210 bcr-abl with
a high degree of selectivity (19, 20). Using the appearance of
the a-subunit of human hemoglobin (a-globin) as a marker for
the induction of erythroid differentiation, we observed that
treatment of K562 cells with 10 mM CGP57148 induced
differentiation (Fig. 5 Bottom Left).
It was not possible to generate stable K562 cell lines
overexpressing the PTPs; therefore, PTP1B, TCPTP, or the
control vector (pcDNA3) were introduced transiently into the
FIG. 3. Effect of overexpression of PTP1B or TCPTP on growth
of p210 bcr-abl-transformed Rat-1 fibroblasts in reduced serum. The
indicated cell lines were initially maintained in 10% FBS, then
switched to 1% FBS on day 0. Cell numbers were counted and the
media was changed at 2-day intervals. The graph presents the data as
the mean 6 SEM from three independent experiments, performed in
duplicate on each of the two independent p210 bcr-abl-transformed
Rat-1 clonal lines (clones 5 and 10) overexpressing the PTPs. Parental
Rat-1 fibroblasts grown in 1% serum were included as a control.
FIG. 4. Effect of overexpression of PTP1B or TCPTP on the
association of Grb2 with p210 bcr-abl. Cell lysates (300 mg) from p210
bcr-abl-transformed clone 5 overexpressing PTP1B, PTP1B-D181A,
TCPTP, or a control vector were prepared, and p210 bcr-abl was
immunoprecipitated by using anti-Abl antibody K12 (lanes A). Im-
munoprecipitates were resolved by SDSyPAGE, transferred to nitro-
cellulose, and immunoblotted with anti-Grb2 antibody (Upper) or
anti-Abl antibody 8E9 (Lower), as a control to illustrate constant levels
of p210 bcr-abl. Lanes L depict 25 mg of cell lysate. Immunoblots were
visualized by ECL.
Table 1. PTP1B and PTP1B-D181A proteins inhibit the growth of p210 bcr-abl-transformed cells in
soft agar
Construct
No. of colonies
per 104 cells
Acidification
No. of colonies
per 104 cells
AcidificationRat-1 Rat-1yp210 Rat-1v-Abl
Vector 2.0 6 1.2 A 676 6 30 11 1732 6 71 11
B 669 6 17 11
PTP1B 1.5 6 1.1 A 265 6 10 2 1826 6 65 11
B 260 6 19 2
PTP1B-D181A 1.8 6 0.8 A 325 6 26 2 1782 6 40 11
B 309 6 17 2
TCPTP 0.5 6 0.5 A 608 6 23 11 1715 6 54 11
B 589 6 9 11
Biochemistry: LaMontagne et al. Proc. Natl. Acad. Sci. USA 95 (1998) 14097
Ph-positive K562 cells by electroporation. After transfection
and 48–60 h of culture in the presence of G418, cells were
harvested and the levels of various proteins were determined
by immunoblotting (Fig. 5). In each experiment, the level of
ectopically expressed PTP1B was $2-fold that of the endog-
enous protein (Fig. 5 Top Left) and the level of TCPTP was
increased 3- to 4-fold over the endogenous protein (Fig. 5
Middle Left). The expression of p210 bcr-abl in these cells was
unchanged (Fig. 5 Top Right). Under these conditions, we
observed an increase in a-globin levels in cells overexpressing
PTP1B but not after overexpression of TCPTP (Fig. 5 Bottom
Left). Furthermore, the level of phosphotyrosine also was
markedly reduced in K562 cells overexpressing PTP1B, or
treated with CGP57148, but less significantly in those cells
overexpressing TCPTP (Fig. 5 Bottom Right). These data
suggest that p210 bcr-abl may transform hematopoietic cells in
part by blocking normal differentiation and that a specific
inhibitor of the PTK (CGP57148) or a natural antagonist
(PTP1B) may overcome this block.
DISCUSSION
CML represents one of the best defined examples in which
aberrant protein tyrosine phosphorylation is the underlying
cause of a human neoplasia (8). Deregulation of the activity of
the Abl PTK domain in p210 bcr-abl, relative to c-Abl, results
in aberrant tyrosine phosphorylation, which engenders the
pathological effects of the oncoprotein PTK. Consequently,
much research effort has focused on characterizing the aber-
rant signaling function of p210 bcr-abl. Nevertheless, it is
important to consider that the state of tyrosine phosphoryla-
tion of proteins in vivo is governed by the coordinated actions
of both PTKs and PTPs (12, 13). However, the analysis of the
effects of PTPs on p210 bcr-abl function has remained largely
unexplored. Characterization of the PTPs that control p210
bcr-abl function, or are themselves subject to regulation by
p210 bcr-abl, represents an essential step toward gaining an
understanding of the physiological changes that result in CML
and in offering potential means through which the disease may
be countered.
Our work has focused attention on PTP1B as a potential
physiological antagonist of p210 bcr-abl. PTP1B is the proto-
typical PTP that was the first member of the family isolated in
homogeneous form (26). It comprises an N-terminal catalytic
domain fused to a regulatory C-terminal segment. The ex-
treme C terminus is characterized by a stretch of 35 residues
that are predominantly hydrophobic and both necessary and
sufficient for targeting PTP1B to the cytoplasmic face of
membranes of the endoplasmic reticulum (27). In light of this
subcellular distribution, one would anticipate that PTP1B will
be exposed to a substantial array of cellular phosphotyrosyl
proteins. However, at present, insights into the physiological
function of PTP1B are somewhat limited. PTP1B can revert
partially the transformation of 3T3 cells by v-Src (28), protect
3T3 cells from transformation by Neu (29), and inhibit IL-3-
dependent signaling in 32D-cl3 cells (30). More recently, it has
been suggested that overexpression of PTP1B in Rat 3Y1 cells
inhibits integrin-dependent signaling (31). In addition, the
observation that PTP1B interacts with the insulin receptor (32,
33), together with the application of strategies involving over-
expression (34) and the use of inhibitory antibodies (35), has
implicated PTP1B in negative regulation of insulin signaling.
However, it is unclear at present whether these observations
reflect normal physiological functions of PTP1B and whether
there is specificity for PTP1B in these processes.
The basis for the present study of the effects of PTP1B on
p210 bcr-abl-induced transformation is our observation that
the levels of PTP1B were enhanced rapidly and specifically in
response to expression of p210 bcr-abl in several CML model
systems (15). The specific induction of PTP1B by p210 bcr-abl
suggests a role for this PTP in modulating the signaling events
initiated by the oncoprotein PTK. However, PTP1B could
either serve a permissive role in mediating signaling or func-
tion as an antagonist. The use of substrate trapping mutants
revealed that PTP1B recognizes p210 bcr-abl directly as a
substrate, but does not recognize v-Abl (15). Furthermore,
PTP1B inhibits signaling events initiated by p210 bcr-abl, but
not v-Abl (15). Such observations clearly suggest that PTP1B
may be a physiological antagonist of p210 bcr-abl function but
do not address the fundamentally important issue of whether
PTP1B can suppress the transforming potential of this onco-
protein PTK.
In this study, we show that expression of either wild-type or
substrate-trapping mutant forms of PTP1B abrogated p210
bcr-abl-induced transformation. This was manifested in the
ability of PTP1B to inhibit the anchorage-independent growth,
proliferation under reduced serum conditions, and tumor
formation in nude mice displayed by p210 bcr-abl transformed
fibroblasts. Particularly striking was the observation that the
elements of specificity were maintained. Although PTP1B
inhibited p210 bcr-abl-induced transformation, there was no
detectable effect on transformation induced by v-Abl. Fur-
thermore, we did not observe an effect of TCPTP on trans-
formation induced by either PTK. The profound inhibitory
effect of PTP1B on p210 bcr-abl-induced transformation is
highlighted in Fig. 1. After expression of p210 bcr-abl, the
levels of PTP1B were enhanced and changes in tyrosine
phosphorylation were minor in the mass population of Rat-1
fibroblasts. Upon selection in soft agar, the levels of PTP1B in
the clonal transformed lines that were recovered had declined
to those observed in the parental cells and enhanced tyrosine
FIG. 5. Effect of overexpression of PTP1B or TCPTP on differ-
entiation of K562 cells. K562 cells were transiently transfected with
pcDNA3 (control vector), pcDNA3-PTP1B, or pcDNA3-TCPTP ex-
pression plasmids. An additional aliquot of control vector-transfected
K562 cells were further treated with 10 mM CGP57148 for 48 h. Lysates
from each condition were analyzed by immunoblotting with anti-
PTP1B antibody (Top Left), and the blot was stripped and reprobed
with anti-TCPTP antibody (Middle Left). This blot also was probed
with anti-a-globin antibody (Bottom Left). The expression and acti-
vation status of endogenous p210 bcr-abl were analyzed by immuno-
blotting with anti-pTyr antibody (Bottom Right) and the blot was
stripped and reprobed with anti-Abl antibody 8E9 (Top Right). Im-
munoblots were visualized by ECL.
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phosphorylation was then apparent. Ectopic overexpression of
PTP1B in the transformed cells resulted in marked tyrosine
dephosphorylation and abrogation of the transformed pheno-
type. In the small number of clones that were recovered upon
culture in soft agar after ectopic expression of PTP1B, it was
observed that the levels of the phosphatase were suppressed.
These data reveal that expression of p210 bcr-abl and PTP1B
may be coupled as a mutually antagonistic pair of activities in
vivo.
It has been shown that p210 bcr-abl autophosphorylates on
several sites, one of which, Y177, serves as a docking site for
the adaptor protein Grb2 (16). Interaction with Grb2 initiates
assembly of a multiprotein complex including SOS leading to
the activation of Ras, which is known to be important for p210
bcr-abl-induced transformation (16, 23, 36–38). Mutation of
Tyr-177 3 Phe or expression of dominant-negative mutant
forms of Ras and Grb2 has been shown to inhibit transforma-
tion by p210 bcr-abl (16, 39, 40). In this study, we observed that
overexpression of either wild-type or substrate-trapping mu-
tant PTP1B disrupted the association between endogenous
Grb2 and p210 bcr-abl, which likely reflects one mechanism by
which inhibition of p210 bcr-abl-induced transformation by
PTP1B is achieved. However, PTP1B recognizes additional
sites in p210 bcr-abl (15) and thus may abrogate other signaling
events triggered by the PTK. Recently, it was shown that
overexpression of PTP1B can inhibit transformation of Rat
3Y1 cells by v-Crk, v-Src, and v-Ras (41). It was suggested that
the ability of PTP1B to suppress transformation in these cells
correlated with the phosphorylation status of p130cas, a cy-
toskeletal protein that interacts with a Pro-rich sequence in
PTP1B. However, we did not observe any change in the
phosphorylation status of p130cas in Rat-1 fibroblasts trans-
formed by p210 bcr-abl (data not shown). In contrast, our data
suggest that PTP1B inhibits p210 bcr-abl-induced transforma-
tion directly through dephosphorylation of the PTK, thus
abrogating downstream signaling events.
CML, which is initiated by the generation of the Ph1
chromosome and the expression of p210 bcr-abl, displays a
predictable progression from a relatively benign chronic phase
to a lethal acute leukemia, known as blast crisis. In the chronic
phase of CML, the stem cells differentiate into various types
of progenitor cells but in larger numbers than normal hema-
topoiesis (8). However, these cells retain the ability to differ-
entiate into mature blood cells. Later, in the blast-crisis phase
of CML, the progenitor cells no longer differentiate. It is
interesting to speculate that perhaps in the chronic phase of the
disease the function of the p210 bcr-abl PTK oncoprotein is
suppressed by PTP1B and thus chronic phase CML progenitor
cells are almost indistinguishable from their normal counter-
parts. However, after one of the many ‘‘secondary hits’’ that
accompany progression into blast crisis, the effects of PTP1B
may be lost, allowing p210 bcr-abl to exert its effects un-
checked. Perhaps PTP1B offers a novel potential avenue for
therapeutic intervention in CML.
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